Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

被引:679
|
作者
Stringhini, Silvia [1 ,11 ,18 ]
Wisniak, Ania [15 ]
Piumatti, Giovanni [1 ,19 ]
Azman, Andrew S. [15 ,20 ]
Lauer, Stephen A. [20 ]
Baysson, Helene [11 ]
De Ridder, David [11 ]
Petrovic, Dusan [1 ,18 ]
Schrempft, Stephanie [1 ]
Marcus, Kailing [1 ]
Yerly, Sabine [2 ,3 ,4 ]
Vernez, Isabelle Arm [3 ,4 ]
Keiser, Olivia [15 ]
Hurst, Samia [16 ]
Posfay-Barbe, Klara M. [5 ]
Trono, Didier [21 ]
Pittet, Didier [6 ,7 ]
Getaz, Laurent [8 ,11 ]
Chappuis, Francois [9 ,11 ]
Eckerle, Isabella [3 ,4 ,12 ]
Vuilleumier, Nicolas [2 ,14 ]
Meyer, Benjamin [13 ,17 ]
Flahault, Antoine [9 ,11 ,15 ]
Kaiser, Laurent [3 ,4 ,10 ,14 ]
Guessous, Idris [1 ,11 ]
机构
[1] Geneva Univ Hosp, Div Primary Care, CH-1205 Geneva, Switzerland
[2] Geneva Univ Hosp, Div Lab Med, Geneva, Switzerland
[3] Geneva Univ Hosp, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland
[4] Geneva Univ Hosp, Lab Virol, Geneva, Switzerland
[5] Geneva Univ Hosp, Div Gen Pediat, Geneva, Switzerland
[6] Geneva Univ Hosp, Infect Prevent & Control Program, Geneva, Switzerland
[7] Geneva Univ Hosp, World Hlth Org Collaborating Ctr Patient Safety, Geneva, Switzerland
[8] Geneva Univ Hosp, Div Penitentiary Med, Geneva, Switzerland
[9] Geneva Univ Hosp, Div Trop & Humanitarian Med, Geneva, Switzerland
[10] Geneva Univ Hosp, Div Infect Dis, Geneva, Switzerland
[11] Univ Geneva, Dept Hlth & Community Med, Fac Med, Geneva, Switzerland
[12] Univ Geneva, Fac Med, Dept Microbiol & Mol Med, Geneva, Switzerland
[13] Univ Geneva, Dept Pathol & Immunol, Fac Med, Ctr Vaccinol, Geneva, Switzerland
[14] Univ Geneva, Dept Med, Fac Med, Geneva, Switzerland
[15] Univ Geneva, Fac Med, Inst Global Hlth, Geneva, Switzerland
[16] Univ Geneva, Inst Eth, Hist, Humanites, Geneva, Switzerland
[17] Univ Geneva, Ctr Vaccinol, Dept Pathol & Immunol, Geneva, Switzerland
[18] Univ Lausanne, Univ Ctr Gen Med & Publ Hlth, Lausanne, Switzerland
[19] Univ Svizzera Italiana, Fac BioMed, Lugano, Switzerland
[20] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[21] Ecole Polytech Fed Lausanne, Sch Life Sci, Lausanne, Switzerland
来源
LANCET | 2020年 / 396卷 / 10247期
关键词
D O I
10.1016/S0140-6736(20)31304-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic. Methods The SEROCoV-POP study is a population-based study of former participants of the Bus Sante study and their household members. We planned a series of 12 consecutive weekly serosurveys among randomly selected participants from a previous population-representative survey, and their household members aged 5 years and older. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. We estimated seroprevalence using a Bayesian logistic regression model taking into account test performance and adjusting for the age and sex of Geneva's population. Here we present results from the first 5 weeks of the study. Findings Between April 6 and May 9, 2020, we enrolled 2766 participants from 1339 households, with a demographic distribution similar to that of the canton of Geneva. In the first week, we estimated a seroprevalence of 4 center dot 8% (95% CI 2 center dot 4-8 center dot 0, n=341). The estimate increased to 8 center dot 5% (5 center dot 9-11 center dot 4, n=469) in the second week, to 10 center dot 9% (7 center dot 9-14 center dot 4, n=577) in the third week, 6 center dot 6% (4 center dot 3-9 center dot 4, n=604) in the fourth week, and 10 center dot 8% (8 center dot 2-13 center dot 9, n=775) in the fifth week. Individuals aged 5-9 years (relative risk [RR] 0 center dot 32 [95% CI 0 center dot 11-0 center dot 63]) and those older than 65 years (RR 0 center dot 50 [0 center dot 28-0 center dot 78]) had a significantly lower risk of being seropositive than those aged 20-49 years. After accounting for the time to seroconversion, we estimated that for every reported confirmed case, there were 11 center dot 6 infections in the community. Interpretation These results suggest that most of the population of Geneva remained uninfected during this wave of the pandemic, despite the high prevalence of COVID-19 in the region (5000 reported clinical cases over <2 center dot 5 months in the population of half a million people). Assuming that the presence of IgG antibodies is associated with immunity, these results highlight that the epidemic is far from coming to an end by means of fewer susceptible people in the population. Further, a significantly lower seroprevalence was observed for children aged 5-9 years and adults older than 65 years, compared with those aged 10-64 years. These results will inform countries considering the easing of restrictions aimed at curbing transmission. Copyright (c) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:313 / 319
页数:7
相关论文
共 50 条
  • [31] Prevalence of salivary anti-SARS-CoV-2 IgG antibodies in vaccinated children
    Badano, Maria Noel
    Duarte, Alejandra
    Salamone, Gabriela
    Sabbione, Florencia
    Pereson, Matias
    Chuit, Roberto
    Bare, Patricia
    IMMUNOLOGY, 2023, 169 (03) : 384 - 387
  • [32] Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies
    Yousefi, Zahra
    Taheri, Niloofar
    Dargahi, Motahareh
    Chaman, Reza
    Binesh, Ehsan
    Emamian, Mohammad Hassan
    Jafari, Reza
    CURRENT MICROBIOLOGY, 2022, 79 (04)
  • [33] Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies
    Zahra Yousefi
    Niloofar Taheri
    Motahareh Dargahi
    Reza Chaman
    Ehsan Binesh
    Mohammad Hassan Emamian
    Reza Jafari
    Current Microbiology, 2022, 79
  • [34] Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies
    Reinig, Sebastian
    Shih, Shin-Ru
    BIOMEDICAL JOURNAL, 2024, 47 (01)
  • [35] Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy
    Paduano, Stefania
    Galante, Pasquale
    Berselli, Nausicaa
    Ugolotti, Luca
    Modenese, Alberto
    Poggi, Alessandro
    Malavolti, Marcella
    Turchi, Sara
    Marchesi, Isabella
    Vivoli, Roberto
    Perlini, Paola
    Bellucci, Rossana
    Gobba, Fabriziomaria
    Vinceti, Marco
    Filippini, Tommaso
    Bargellini, Annalisa
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (13)
  • [36] High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
    Gelanew, Tesfaye
    Seyoum, Berhanu
    Mulu, Andargachew
    Mihret, Adane
    Abebe, Markos
    Wassie, Liya
    Gelaw, Baye
    Sorsa, Abebe
    Merid, Yared
    Muchie, Yilkal
    Teklemariam, Zelalem
    Tesfaye, Bezalem
    Osman, Mahlet
    Jebessa, Gutema
    Atinafu, Abay
    Hailu, Tsegaye
    Habte, Antenehe
    Kenea, Dagaga
    Gadisa, Anteneh
    Admasu, Desalegn
    Tesfaye, Emnet
    Bates, Timothy A.
    Bulcha, Jote Tafese
    Tschopp, Rea
    Tsehay, Dareskedar
    Mullholand, Kim
    Howe, Rawleigh
    Genetu, Abebe
    Tafesse, Fikadu G.
    Abdissa, Alemseged
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [37] About population tests to detect anti-SARS-CoV-2 antibodies
    Kantor, Isabel N.
    Ritacco, Viviana
    MEDICINA-BUENOS AIRES, 2020, 80 : 87 - 88
  • [38] Seroprevalence of anti-SARS-CoV-2 antibodies in Japanese COVID-19 patients
    Hiki, Makoto
    Tabe, Yoko
    Ai, Tomohiko
    Matsue, Yuya
    Harada, Norihiro
    Sugimoto, Kiichi
    Matsushita, Yasushi
    Matsushita, Masakazu
    Wakita, Mitsuru
    Misawa, Shigeki
    Idei, Mayumi
    Miida, Takashi
    Tamura, Naoto
    Takahashi, Kazuhisa
    Naito, Toshio
    PLOS ONE, 2021, 16 (04):
  • [39] Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea
    Noh, Ji Yun
    Seo, Yu Bin
    Yoon, Jin Gu
    Seong, Hye
    Hyun, Hakjun
    Lee, Jacob
    Lee, Nuri
    Jung, Seri
    Park, Min-Jeong
    Song, Wonkeun
    Yoon, Jung
    Lim, Chae Seung
    Ryou, Jungsang
    Lee, Joo-Yeon
    Kim, Sung-Soon
    Cheong, Hee Jin
    Kim, Woo Joo
    Yoon, Soo-Young
    Song, Joon Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (33)
  • [40] A study of anti-SARS-CoV-2 antibodies among healthcare personnel and the general population
    Trifonova, Iva
    Ngoc, Kim
    Gladnishka, Teodora
    Ivanova, Vladislava
    Kunchev, Metodi
    Mutafchiyski, Ventsislav
    Christova, Iva
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2023, 37 (01)